Cyclic peptide-based nanostructures as efficient siRNA carriers (2018)
Sequence: Cyclo[WRGGGWRGGG]
| Experiment Id | EXP001461 |
|---|---|
| Paper | Cyclic peptide-based nanostructures as efficient siRNA carriers |
| Peptide | CP V |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | medium |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | Uptake: 30 µM (FACS) or ~8 µM (confocal). Knockdown: 24 µM. |
| Rna Concentration | Uptake: 200 nM (FACS) or ~80 nM (confocal). Knockdown: 600 nM. |
| Mixing Ratio | Confocal: 0.04 nmol FAM-siRNA + 4 nmol peptide in 500 µL DMEM, 30 min complexation. FACS: 200 nM FAM-siRNA + 30 µM peptide in Opti-MEM, 30 min. Western blot: 24 µM peptide + 600 nM GAPDH siRNA in 500 µL serum-free DMEM, 30 min; incubate cells 3 h then add complete media and culture 48 h. |
| Formulation Format | Self-assembled cyclic peptide nanostructures / peptide–siRNA nanocomplexes (noncovalent) |
| Formulation Components | CP V + GAPDH siRNA (FAM-labeled for uptake; unlabeled for knockdown) |
| Size Nm | 195.20 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HCT116 human colon cancer cells |
| Animal Model | |
| Administration Route | |
| Output Type | Uptake (confocal microscopy + flow cytometry) and functional gene silencing (GAPDH protein by Western blot) |
| Output Value | |
| Output Units | |
| Output Notes | Did not significantly influence FAM-siRNA uptake (reported as not significant; data not shown). No functional gene-silencing result reported. |
| Toxicity Notes | Cyclic peptides showed >90% viability at 10 µM (24 h). siRNA/peptide complexes showed no significant cytotoxicity except CP I showed some cytotoxicity relative to other complexes; lipofectamine 2000 showed significant cytotoxicity. |
| Curation Notes |